Vision & Mission

The Pediatric Praziquantel Consortium is an international partnership that aims to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children. The neglected tropical disease affects more than 200 million people worldwide, including at least 25 million preschool-age children that are currently lacking adequate treatment. The Consortium operates on a not-for-profit basis.

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers. 

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

To accomplish its mission:

  • The Consortium combines some of the best science and most experienced public and private partners to develop and provide a new pediatric formulation of praziquantel to treat schistosomiasis. Read more
     
  • The Consortium operates through an innovative approach that engages new partners as needed. Beyond the partners contributing expertise and resources, the Consortium pro-actively promotes dialogue at all stakeholder levels and consults international academics, experts from endemic countries, funding agencies, the WHO and non-governmental organizations. Read more 
     
  • The pediatric formulation developed by the Consortium is a small, orally dispersible tablet with an acceptable taste. It should also withstand the challenges presented by a tropical climate. Read more
     
  • The clinical program comprises of a full phase I-III development program, set up in line with EMA recommendations for pediatric development. It has been designed with the support of regulatory authorities and a panel of international experts, including clinicians from endemic countries. Read more
     
  • The Consortium, in case of a successful outcome of the clinical program, aims to obtain a positive Article 58 opinion from the EMA in 2022, followed by WHO prequalification and local regulatory approval of Levo-Praziquantel 150mg in the first African priority countries through the collaborative procedure pathway. Apart from EMA, the Marketing Authorization Application shall be submitted in Brazil
     
  • Once approved, the product will be made available on a not-for-profit basis.Together with relevant stakeholders, the Consortium is exploring new procurement and business models, including local manufacturing, to ensure that the product is available free of charge to the young patients in need.